Telix Publishes ProstACT SELECT Study on TLX591-Tx
Melbourne, Australia & Indianapolis, Indiana, USA | July 22, 2026 Telix Pharmaceuticals announced the peer-reviewed publication of results from...
Metastatic Castration-Resistant Prostate Cancer
Advertisement
ORIC Launches Phase 3 Himalayas-1 Trial
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 ORIC Pharmaceuticals announced the initiation of the global Himalayas-1...
Telix Secures FDA Alignment to Advance ProstACT Phase 3 Trial
Melbourne, Australia, and Indianapolis, Indiana, United States, July 2, 2026 Telix announced a significant regulatory milestone after a successful...
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Convergent’s CONV01-α Shows Promising Activity in Post-Lu-PSMA Prostate Cancer Phase 2 Study
CAMBRIDGE, Mass., June 2, 2026 Convergent Therapeutics announced positive interim Phase 2 data from its CONVERGE-01 study evaluating CONV01-α...
Advertisement
